Gerometabolites: The pseudohypoxic aging side of cancer oncometabolites
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Oncometabolites are defined as small-molecule components (or enantiomers) of normal metabolism whose accumulation causes signaling dysregulation to establish a milieu that initiates carcinogenesis. In a similar manner, we propose the term "gerometabolites" to refer to small-molecule components of normal metabolism whose depletion causes signaling dysregulation to establish a milieu that drives aging. In an investigation of the pathogenic activities of the currently recognized oncometabolites R(-)-2-hydroxyglutarate (2-HG), fumarate, and succinate, which accumulate due to mutations in isocitrate dehydrogenases (IDH), fumarate hydratase (FH), and succinate dehydrogenase (SDH), respectively, we illustrate the fact that metabolic pseudohypoxia, the accumulation of hypoxia-inducible factor (HIFα) under normoxic conditions, and the subsequent Warburg-like reprogramming that shifts glucose metabolism from the oxidative pathway to aerobic glycolysis are the same mechanisms through which the decline of the "gerometabolite" nicotinamide adenine dinucleotide (NAD)(+) reversibly disrupts nuclear-mitochondrial communication and contributes to the decline in mitochondrial function with age. From an evolutionary perspective, it is reasonable to view NAD(+)-driven mitochondrial homeostasis as a conserved response to changes in energy supplies and oxygen levels. Similarly, the natural ability of 2-HG to significantly alter epigenetics might reflect an evolutionarily ancient role of certain metabolites to signal for elevated glutamine/glutamate metabolism and/or oxygen deficiency. However, when chronically altered, these responses become conserved causes of aging and cancer. Because HIFα-driven pseudohypoxia might drive the overproduction of 2-HG, the intriguing possibility exists that the decline of gerometabolites such as NAD(+) could promote the chronic accumulation of oncometabolites in normal cells during aging. If the sole activation of a Warburg-like metabolic reprogramming in normal tissues might be able to significantly increase the endogenous production of bona fide etiological determinants in cancer, such as oncometabolites, this undesirable trade-off between mitochondrial dysfunction and activation of oncometabolites production might then pave the way for the epigenetic initiation of carcinogenesis in a strictly metabolic-dependent manner. Perhaps it is time to definitely adopt the view that aging and aging diseases including cancer are governed by a pivotal regulatory role of metabolic reprogramming in cell fate decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108 · cited 1×
“1).(29-36) Succinate was initially found to impair PHD2, the α-ketoglutarate-dependent enzyme regulating HIFα stability, through product inhibition, and subsequent work confirmed that succinate could also inhibit the related enzyme PHD3.”
BackgroundWard, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Sirtuins as regulators of metabolism and healthspan
Houtkooper, R. H., Pirinen, E., & Auwerx, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3293 · Cited by 2,008
Sirtuin activators mimic caloric restriction and delay ageing in metazoans
Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand, S. L., Tatar, M., & Sinclair, D. (2004) · Nature · doi:10.1038/nature02789 · Cited by 1,868
Price, N. L., Gomes, A. P., Ling, A. J. Y., Duarte, F. V., Martin-Montalvo, A., North, B. J., Agarwal, B., Ye, L., Ramadori, G., Teodoro, J. S., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.003 · Cited by 1,602
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575 · cited 1×
“The “oncogene from hell”,(98) Myc, is a critical link between altered cellular metabolism and the genesis of many human cancers.(99-104) c-Myc regulates genes involved in the biogenesis of ribosomes and mitochondria as well as the regulation of glucose and glutamine metabolism but can also induce DNA damage, increase…”
BackgroundHIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Semenza, G. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67230 · Cited by 1,335
Tumor suppressors and cell metabolism: a recipe for cancer growth
Jones, R. G., & Thompson, C. B. (2009) · Genes & Development · doi:10.1101/gad.1756509 · Cited by 1,085
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035 · cited 2×
“Thus, proto-oncogenes and tumor suppressors possibly originated through evolution as components of metabolic regulation and, more importantly, so-called oncometabolites can directly impair the normal epigenetic regulation of cell differentiation and alter cell signaling to drive cellular transformation and oncogenesis…”
BackgroundWise, D. R., Ward, P. S., Shay, J. E. S., Cross, J. R., Gruber, J. J., Sachdeva, U. M., Platt, J. M., DeMatteo, R. G., Simon, M. C., & Thompson, C. B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117773108 · Cited by 975 · cited 1×
“For example, in human cells proliferating under hypoxia, α-ketoglutarate can accumulate and be metabolized through an enhanced reductive activity of wild-type IDH2 in the mitochondria, leading to 2-HG accumulation.(125) Crucially, the constitutive activation of HIF-1α is sufficient to recapitulate IDH2-dependent carbo…”
BackgroundMYC as a regulator of ribosome biogenesis and protein synthesis
van Riggelen, J., Yetil, A., & Felsher, D. W. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2819 · Cited by 956
Nutrient-Sensitive Mitochondrial NAD+ Levels Dictate Cell Survival
Yang, H., Yang, T., Baur, J. A., Perez, E., Matsui, T., Carmona, J. J., Lamming, D. W., Souza-Pinto, N. C., Bohr, V. A., Rosenzweig, A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.07.035 · Cited by 950
Cantó, C., Jiang, L. Q., Deshmukh, A. S., Mataki, C., Coste, A., Lagouge, M., Zierath, J. R., & Auwerx, J. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.02.006 · Cited by 921 · cited 1×
“com Cell Cycle 705 the deacetylation and modulation of the activity of downstream SIRT1 targets that include the PGC-1α transcription factor.(85-87) We know that, in response to metformin, SIRT1 can be activated through an AMPK-mediated increase in gene expression in nicotinamide phosphoribosyltransferase, the rate-li…”
BackgroundTargeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804
SDH mutations establish a hypermethylator phenotype in paraganglioma
Letouzé, E., Martinelli, C., Loriot, C., Burnichon, N., Abermil, N., Ottolenghi, C., Janin, M., Menara, M., Nguyen, A. T., Benit, P., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.018 · Cited by 776 · cited 2×
“Thus, proto-oncogenes and tumor suppressors possibly originated through evolution as components of metabolic regulation and, more importantly, so-called oncometabolites can directly impair the normal epigenetic regulation of cell differentiation and alter cell signaling to drive cellular transformation and oncogenesis…”
BackgroundTransformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012) · Nature · doi:10.1038/nature10898 · Cited by 727
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Losman, J.-A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., Cowley, G. S., Root, D. E., Ebert, B. L., & Kaelin, W. G. (2013) · Science · doi:10.1126/science.1231677 · Cited by 703
The updated biology of hypoxia-inducible factor
Greer, S. N., Metcalf, J. L., Wang, Y., & Ohh, M. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.125 · Cited by 545
Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
Cairns, R. A., & Mak, T. W. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0083 · Cited by 452 · cited 2×
“Thus, proto-oncogenes and tumor suppressors possibly originated through evolution as components of metabolic regulation and, more importantly, so-called oncometabolites can directly impair the normal epigenetic regulation of cell differentiation and alter cell signaling to drive cellular transformation and oncogenesis…”
BackgroundA HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas
Dahia, P. L. M., Ross, K. N., Wright, M. E., Hayashida, C. Y., Santagata, S., Barontini, M., Kung, A. L., Sanso, G., Powers, J. F., Tischler, A. S., et al. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010008 · Cited by 443
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis
Terunuma, A., Putluri, N., Mishra, P., Mathé, E. A., Dorsey, T. H., Yi, M., Wallace, T. A., Issaq, H. J., Zhou, M., Killian, J. K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71180 · Cited by 428 · cited 4×
“A recent, pioneering study by Terunuma et al.124 revealed that the oncometabolite 2-HG accumulates at high levels in a subset of tumors and human breast cancer cell lines.124 Importantly, the activation of the Myc pathway mechanistically phenocopied IDH mutations, which were absent in 2-HG-overexpressing breast carcin…”
BackgroundInfluentialGimenez-Roqueplo, A.-P., Favier, J., Rustin, P., Mourad, J.-J., Plouin, P.-F., Corvol, P., Rötig, A., & Jeunemaitre, X. (2001) · The American Journal of Human Genetics · doi:10.1086/324413 · Cited by 364 · cited 1×
“1).(29-36) Succinate was initially found to impair PHD2, the α-ketoglutarate-dependent enzyme regulating HIFα stability, through product inhibition, and subsequent work confirmed that succinate could also inhibit the related enzyme PHD3.”
BackgroundMacKenzie, E. D., Selak, M. A., Tennant, D. A., Payne, L. J., Crosby, S., Frederiksen, C. M., Watson, D. G., & Gottlieb, E. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01927-06 · Cited by 359 · cited 1×
“For example, the introduction of cell-permeating α-ketoglutarate derivatives has been shown to restore normal PHD activity, which targets HIF1α for ubiquitylation and proteasomal degradation.(96) This restores normal, low levels of HIF1α in SDH-deficient cells, thus indicating that pharmacological elevation of intrace…”
BackgroundThe Proto-oncometabolite Fumarate Binds Glutathione to Amplify ROS-Dependent Signaling
Sullivan, L. B., Martinez-Garcia, E., Nguyen, H., Mullen, A. R., Dufour, E., Sudarshan, S., Licht, J. D., Deberardinis, R. J., & Chandel, N. S. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.05.003 · Cited by 304 · cited 2×
“Thus, proto-oncogenes and tumor suppressors possibly originated through evolution as components of metabolic regulation and, more importantly, so-called oncometabolites can directly impair the normal epigenetic regulation of cell differentiation and alter cell signaling to drive cellular transformation and oncogenesis…”
BackgroundZheng, Z., Chen, H., Li, J., Li, T., Zheng, B., Zheng, Y., Jin, H., He, Y., Gu, Q., & Xu, X. (2012) · Diabetes · doi:10.2337/db11-0416 · Cited by 282
The sirtuins, oxidative stress and aging: an emerging link
Merksamer, P. I., Liu, Y., He, W., Hirschey, M. D., Chen, D., & Verdin, E. (2013) · Aging · doi:10.18632/aging.100544 · Cited by 275
Blagosklonny, M. V. (2012) · Aging · doi:10.18632/aging.100443 · Cited by 251
Turcan, S., Fabius, A. W. M., Borodovsky, A., Pedraza, A., Brennan, C., Huse, J., Viale, A., Riggins, G. J., & Chan, T. A. (2013) · Oncotarget · doi:10.18632/oncotarget.1412 · Cited by 240 · cited 1×
“Indeed, the oncogenic activity of the (R)-2HG oncometabolite likely relies on its ability to epigenetically block the acquisition of differentiation markers while inducing the expression of stem cellmaintenance genes.(4,20,22,25,26) Loss-of-function mutations in tumor suppressor genes encoding the Krebs cycle enzymes…”
BackgroundHewitson, K. S., Liénard, B. M. R., McDonough, M. A., Clifton, I. J., Butler, D., Soares, A. S., Oldham, N. J., McNeill, L. A., & Schofield, C. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608337200 · Cited by 235 · cited 1×
“1).(29-36) Succinate was initially found to impair PHD2, the α-ketoglutarate-dependent enzyme regulating HIFα stability, through product inhibition, and subsequent work confirmed that succinate could also inhibit the related enzyme PHD3.”
BackgroundThe Warburg effect is genetically determined in inherited pheochromocytomas
Favier, J., Brière, J.-J., Burnichon, N., Rivière, J., Vescovo, L., Benit, P., Giscos-Douriez, I., De Reyniès, A., Bertherat, J., Badoual, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007094 · Cited by 232 · cited 1×
“1).(29-36) Succinate was initially found to impair PHD2, the α-ketoglutarate-dependent enzyme regulating HIFα stability, through product inhibition, and subsequent work confirmed that succinate could also inhibit the related enzyme PHD3.”
BackgroundThe emerging role of fumarate as an oncometabolite
Yang, M., Soga, T., Pollard, P. J., & Adam, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00085 · Cited by 189
The VHL tumor suppressor: master regulator of HIF
Haase, V. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789649394 · Cited by 175
Hypoxia suppresses conversion from proliferative arrest to cellular senescence
Leontieva, O. V., Natarajan, V., Demidenko, Z. N., Burdelya, L. G., Gudkov, A. V., & Blagosklonny, M. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205690109 · Cited by 169 · cited 1×
“, mTOR activators) such as insulin, growth factors, hormones, cytokines, and nutrients under normoxia.(79-82) The failure to limit mTOR-dependent induction of HIF-1α may therefore contribute to age-related diseases (Fig.”
BackgroundProlyl hydroxylases as regulators of cell metabolism
Boulahbel, H., Durán, R. V., & Gottlieb, E. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370291 · Cited by 82 · cited 1×
“Intriguingly, given that 2OG is a limiting co-substrate for PHD activity during normoxia, and that 2OG levels depend on amino acid availability, it is plausible that PHD activity depends not only on oxygen or oncometabolites, but also on amino acid availability, suggesting a global metabolic sensor function for PHDs a…”
Background
Cited by
Pastò, A., Bellio, C., Pilotto, G., Ciminale, V., Silic-Benussi, M., Guzzo, G., Rasola, A., Frasson, C., Nardo, G., Zulato, E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2010 · Cited by 293
vel Szic, K. S., Declerck, K., Vidaković, M., & Vanden Berghe, W. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0068-2 · Cited by 192
Sgarbi, G., Matarrese, P., Pinti, M., Lanzarini, C., Ascione, B., Gibellini, L., Dika, E., Patrizi, A., Tommasino, C., Capri, M., et al. (2014) · Aging · doi:10.18632/aging.100654 · Cited by 90
Wang, Y., Liu, B., Li, F., Zhang, Y., Gao, X., Wang, Y., & Zhou, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1274239 · Cited by 18
Metadata
- Authors
- MENENDEZ MENENDEZ, J., ALARCÓN, T., & Joven, J.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2014-02-03
- Volume
- 13
- Issue
- 5
- Pages
- 699-709
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- OpenAlex
- W2046325531
- Cited by
- 40
- References
- 35
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.